Heron Therapeutics

HRTX · NASDAQ

$0.3545−$0.0064 (−1.77%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.3609

About HRTX

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in Cary, North Carolina and currently employs 128 full-time employees. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.

Employees: 128
Headquarters: Cary, North Carolina
Listed: Aug 26, 1987
Sector: Health Care
Industry: Biotechnology
Website: herontx.com

Leadership

Heron Therapeutics executives
Name	Title	Since	Age
Adam Morgan	—	—	46
Craig Collard	—	2023	59
Ira Duarte	—	—	56
Mark Hensley	—	—	42
William Forbes	—	—	63
Craig Johnson	—	—	63
Tom Cusack	—	—	—
Sharmila Dissanaike	—	—	50
Michael Kaseta	—	—	49
Christian Waage	—	—	58

Revenue by product and region

Fiscal year ended Dec 31, 2019: $145.97M total revenue

By product

Represents the information pertaining to the product CINVANTI.$132.20M90.6%
Represents information pertaining to the product SUSTOL.$13.80M9.5%

Similar companies

Companies in the same industry as Heron Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.